Background: Overexpression of tumor-associated calcium signal transducer 2 (Trop2) is found in many tumor entities. The prognostic value of Trop2 in renal cell renal carcinoma (RCC), especially in nonclear cell RCC, is still unclear. Aim: The aim of this study was to evaluate the prognostic impact of Trop2 expression in a large cohort of patients with chromophobe (ch)RCC. Materials and Methods: Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for Trop2 expression by immunohistochemistry. Results: Eighty-one chRCC patients were eligible for analysis, of these 24 (29.6%) patients were positive for Trop2. No significant associations were found for Trop2 expression and clinical attributes in patients with chRCC. The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Trop2 compared to Trop2+ (89.6% vs. 100.0%; p = 0.288). Conclusion: In chRCC, Trop2 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further studies with larger cohorts are warranted.

1.
Lipinski
M
,
Parks
DR
,
Rouse
RV
,
Herzenberg
LA
.
Human trophoblast cell-surface antigens defined by monoclonal antibodies
.
Proc Natl Acad Sci U S A
.
1981 Aug
;
78
(
8
):
5147
50
. .
2.
McDougall
AR
,
Tolcos
M
,
Hooper
SB
,
Cole
TJ
,
Wallace
MJ
.
Trop2: from development to disease
.
Dev Dyn
.
2015 Feb
;
244
(
2
):
99
109
. .
3.
Stein
R
,
Chen
S
,
Sharkey
RM
,
Goldenberg
DM
.
Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting
.
Cancer Res
.
1990 Feb 15
;
50
(
4
):
1330
6
.
4.
Stein
R
,
Basu
A
,
Chen
S
,
Shih
LB
,
Goldenberg
DM
.
Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody
.
Int J Cancer
.
1993 Dec 2
;
55
(
6
):
938
46
. .
5.
Goldenberg
DM
,
Stein
R
,
Sharkey
RM
.
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
.
Oncotarget
.
2018 Jun 22
;
9
(
48
):
28989
9006
. .
6.
Strop
P
,
Tran
TT
,
Dorywalska
M
,
Delaria
K
,
Dushin
R
,
Wong
OK
,
RN927C, a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models
.
Mol Cancer Ther
.
2016 Nov
;
15
(
11
):
2698
708
.
7.
Bardia
A
,
Mayer
IA
,
Diamond
JR
,
Moroose
RL
,
Isakoff
SJ
,
Starodub
AN
,
Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer
.
J Clin Oncol
.
2017 Jul 1
;
35
(
19
):
2141
8
.
8.
King
GT
,
Eaton
KD
,
Beagle
BR
,
Zopf
CJ
,
Wong
GY
,
Krupka
HI
,
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
.
Invest New Drugs
.
2018 Oct
;
36
(
5
):
836
47
.
9.
Moch
H
,
Cubilla
AL
,
Humphrey
PA
,
Reuter
VE
,
Ulbright
TM
.
The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours
.
Eur Urol
.
2016 Jul
;
70
(
1
):
93
105
. .
10.
Erlmeier
F
,
Feuchtinger
A
,
Borgmann
D
,
Rudelius
M
,
Autenrieth
M
,
Walch
AK
,
Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes
.
Histochem Cell Biol
.
2015 Aug
;
144
(
2
):
147
56
.
11.
Kurokawa
Y
,
Matsuura
N
,
Kawabata
R
,
Nishikawa
K
,
Ebisui
C
,
Yokoyama
Y
,
Prognostic impact of major receptor tyrosine kinase expression in gastric cancer
.
Ann Surg Oncol
.
2014 Dec
;
21 Suppl 4
:
S584
90
.
12.
Phan
LM
,
Fuentes-Mattei
E
,
Wu
W
,
Velazquez-Torres
G
,
Sircar
K
,
Wood
CG
,
Hepatocyte growth factor/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma
.
Cancer Res
.
2015 Oct 1
;
75
(
19
):
4131
42
.
13.
Birks
DK
,
Kleinschmidt-DeMasters
BK
,
Donson
AM
,
Barton
VN
,
McNatt
SA
,
Foreman
NK
,
Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors
.
Brain Pathol
.
2010 Jan
;
20
(
1
):
140
50
.
14.
Wang
Q
,
Zhang
Y
,
Zhang
T
,
Han
ZG
,
Shan
L
.
Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer
.
Onco Targets Ther
.
2015
;
8
:
1971
7
. .
15.
Gao
F
,
Li
M
,
Xiang
R
,
Zhou
X
,
Zhu
L
,
Zhai
Y
.
Expression of CLDN6 in tissues of gastric cancer patients: association with clinical pathology and prognosis
.
Oncol Lett
.
2019 May
;
17
(
5
):
4621
5
. .
16.
Theodorescu
D
,
Broder
SR
,
Boyd
JC
,
Mills
SE
,
Frierson
HF
.
Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate
.
Cancer
.
1997 Dec 1
;
80
(
11
):
2109
19
. .
17.
Steffens
S
,
Schrader
AJ
,
Blasig
H
,
Vetter
G
,
Eggers
H
,
Tränkenschuh
W
,
Caveolin 1 protein expression in renal cell carcinoma predicts survival
.
BMC Urol
.
2011 Dec 7
;
11
:
25
.
18.
Steffens
S
,
Schrader
AJ
,
Vetter
G
,
Eggers
H
,
Blasig
H
,
Becker
J
,
Fibronectin 1 protein expression in clear cell renal cell carcinoma
.
Oncol Lett
.
2012 Apr 1
;
3
(
4
):
787
90
.
19.
Shvartsur
A
,
Bonavida
B
.
Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications
.
Genes Cancer
.
2015 Mar
;
6
(
3–4
):
84
105
. .
20.
Fong
D
,
Moser
P
,
Krammel
C
,
Gostner
JM
,
Margreiter
R
,
Mitterer
M
,
High expression of TROP2 correlates with poor prognosis in pancreatic cancer
.
Br J Cancer
.
2008 Oct 21
;
99
(
8
):
1290
5
.
21.
Ohmachi
T
,
Tanaka
F
,
Mimori
K
,
Inoue
H
,
Yanaga
K
,
Mori
M
.
Clinical significance of TROP2 expression in colorectal cancer
.
Clin Cancer Res
.
2006 May 15
;
12
(
10
):
3057
63
. .
22.
Lin
JC
,
Wu
YY
,
Wu
JY
,
Lin
TC
,
Wu
CT
,
Chang
YL
,
TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma
.
EMBO Mol Med
.
2012 Jun
;
4
(
6
):
472
85
.
23.
Katzendorn
O
,
Peters
I
,
Dubrowinskaja
N
,
Tezval
H
,
Tabrizi
PF
,
von Klot
CA
,
DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers
.
BMC Cancer
.
2021 Apr 21
;
21
(
1
):
444
.
24.
Sun
H
,
Chen
Q
,
Liu
W
,
Liu
Y
,
Ruan
S
,
Zhu
C
,
TROP2 modulates the progression in papillary thyroid carcinoma
.
J Cancer
.
2021
;
12
(
22
):
6883
93
.
25.
Kushiyama
S
,
Yashiro
M
,
Yamamoto
Y
,
Sera
T
,
Sugimoto
A
,
Nishimura
S
,
Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
.
Mol Clin Oncol
.
2021 May
;
14
(
5
):
105
.
26.
Guan
GF
,
Zhang
DJ
,
Wen
LJ
,
Yu
DJ
,
Zhao
Y
,
Zhu
L
,
Prognostic value of TROP2 in human nasopharyngeal carcinoma
.
Int J Clin Exp Pathol
.
2015
;
8
(
9
):
10995
1004
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.